CCM
NVS icon

Chiron Capital Management’s Novartis NVS Stock Holding History

Chiron Capital Management’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-500
Closed -$43K – 325
2020
Q3 		$43K Buy
+500
New +$43.3K 0.03% 167

Other funds holding NVS

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Aristotle Capital Management
Aristotle Capital Management Los Angeles, California $47.8B AUM 13.38% 1-Year Est. Return
Mawer Investment Management
Mawer Investment Management Calgary, Alberta, Canada $15.4B AUM 10.9% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Chiron Capital Management's NVS Position: Q4 2020 in Review

Chiron Capital Management sold out of Novartis (NVS) in Q4 2020, closing a stake of 500 shares — an estimated $43K sold.

Chiron Capital Management first reported a position in NVS in Q3 2020 and held it in 1 quarter. The position peaked at $43K in Q3 2020. 1,177 funds tracked by Wall St. Rank hold NVS as of Q4 2020.

  • Chiron Capital Management reported no remaining Novartis position as of Q4 2020 after selling out during the quarter.
  • Chiron Capital Management sold 500 Novartis shares in Q4 2020, an estimated $43K.
  • Chiron Capital Management first reported a position in Novartis in Q3 2020 and held it in 1 quarter.
  • Chiron Capital Management's Novartis position peaked at $43K in Q3 2020.
  • 1,177 funds tracked by Wall St. Rank held Novartis as of Q4 2020.

Based on Chiron Capital Management's 13F filing for Q4 2020, filed 5 Mar 2021.